Form 4: Michelle Seitz Acquires Stock Options in Sana Biotechnology

Director Michelle Seitz acquired stock options in Sana Biotechnology, Inc. on June 6, 2024.

Summary

• Michelle Seitz, a director of Sana Biotechnology, Inc., acquired stock options on June 6, 2024.
• The options grant the right to buy 54,278 shares of common stock at an exercise price of $7.36.
• The options vest on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana.
• Following the transaction, Seitz directly owns 54,278 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director could be interpreted as a mildly positive signal, reflecting confidence in the company's prospects.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continuous service to Sana Biotechnology, suggesting an expectation of ongoing involvement.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with those of shareholders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates